Chloramphenicol Ear Drops Veterinary Grade API is the unesterified chloramphenicol base supplied for downstream manufacture of tablets, injectable preparations, capsules, powders, granules, premixes and otic solutions. The substance is chemically 2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide, with CAS 56-75-7 and molecular formula C11H12Cl2N2O5. The molecular weight is 323.13 g/mol. The API is a white to greyish-white or yellowish-white crystalline powder; its melting point is generally observed between 149 °C and 153 °C. Water solubility is approximately 2.5 mg/mL at 25 °C, while solubility in ethanol and propylene glycol is substantially higher. These solvent-dependent solubility boundaries govern the formulation route: non-aqueous otic products can reach higher concentrations than purely aqueous injectable solutions; tablets and capsules require particle-size and flow control; sterile formats require additional endotoxin and sterility validation. The term “veterinary grade” does not denote reduced purity; it denotes documentation and manufacturing controls aligned with veterinary marketing-authorization dossiers, including VICH GL18 residual solvents and current compendial impurity policies. The product model is defined by the compendial base form and particle-size class rather than a universal commercial code. The API is supplied in non-micronized and micronized classes; each certificate of analysis should state the laser-diffraction d10, d50 and d90 values under USP <429> because no universal particle-size specification exists across all seven listed dosage forms.

Why Does Particulate Behaviour Restrict Direct Compression Loads?

Direct compression of unmodified chloramphenicol base is often not robust because the crystalline powder has a low bulk density and a hydrophobic surface that contributes to poor flowability and variability in die fill. A production-scale tablet line using a rotary press may exhibit weight variation and punch-face sticking when the active fraction exceeds 60% w/w without adequate flow aids. The practical limit is not a fixed pharmacopoeial threshold; it is a function of particle size, moisture and excipient choice. Roller compaction before compression is used to densify the API with microcrystalline cellulose at 20–30% w/w and colloidal silicon dioxide at 0.5–1.0% w/w. Ribbon density fluctuations observed on production-scale roller compactors can occur when the feed screw speed and roll gap are not balanced; this failure mode propagates into granulate particle-size distribution and final content uniformity under USP <905>. Wet granulation using povidone K30 at 3–5% w/w in a high-shear mixer is another route, but the endpoint must be controlled tightly because the API remains largely undissolved and the granules may become brittle after fluid-bed drying above 60 °C. For capsule filling, the milled API is usually granulated or roller-compacted first; direct fill of neat powder can produce unacceptable relative standard deviation in fill weight because of static charging and low tapped density. The final particle-size band should be linked to dissolution or suspension performance, not to a general API label claim. Laser diffraction under USP <429> and optical microscopy under USP <786> provide the particle-size and shape descriptors needed for batch-to-batch comparison.

For otic solutions, propylene glycol and glycerol are commonly selected because chloramphenicol base at 2.5 mg/mL in water cannot support clinically useful concentrations above 0.5% w/v without excessive volume. A non-aqueous otic formulation protects the API against alkaline hydrolysis, which becomes significant at pH above 7.0 and produces 2-amino-1-(4-nitrophenyl)propane-1,3-diol. Trace water in propylene glycol is nevertheless a stability risk; manufacturers control water content by Karl Fischer titration under USP <921>, often with a limit below 1.0% w/w for non-aqueous otic preparations. The otic grade should be free of particulate matter relevant to the finished-product specification; if the ear drop is marketed as sterile, the finished product must satisfy USP <71> sterility and an endotoxin limit derived under USP <85>. Non-sterile otic products do not require those endpoints but still require a validated bioburden control strategy. The API’s solubility in glycerol is lower than in propylene glycol; therefore, a co-solvent system or gentle heating to 40–50 °C may be required during compounding, followed by cooling and filtration through a 0.22 μm membrane where particulate control is required. Exposure to pH above 7.0 during aqueous premixing should be avoided because the amide linkage undergoes hydrolysis and the resulting amine impurity can also alter the pH of the batch.

Solubility and Sterilization Boundaries for Injectable and Otic Formats

Chloramphenicol base is unsuitable for concentrated aqueous injectable solutions without co-solvent or prodrug conversion because 2.5 mg/mL at 25 °C limits the dose that can be delivered in acceptable injection volumes. Parenteral formulations therefore use chloramphenicol sodium succinate or extensive co-solvent systems; the base API is more directly suited to non-aqueous otic and oral solid formats. If a base-containing injectable is attempted, the pH should be maintained below 7.0 to minimise hydrolysis. Terminal steam sterilization at 121 °C for 15 min is not automatically compatible with an aqueous base formulation at pH above 7.0, because hydrolysis can accelerate under alkaline conditions and generate the 2-amino impurity. Aqueous solutions at low pH may be filtered through a 0.22 μm sterilising-grade membrane, but the low solubility limits the utility of this approach. Dry heat sterilization of the pure API powder can be considered only after validation demonstrates no unacceptable increase in related substances; typical dry heat cycles above 140 °C should be evaluated for melting or sublimation behaviour because the API melting point is 149–153 °C. The finished-product manufacturer must also consider that chloramphenicol base in aqueous suspension may aggregate during autoclaving, causing particle-size drift and syringeability failure. For otic formulations, terminal sterilization is less relevant when the product is non-sterile; when sterile otic drops are required, aseptic filtration of a non-aqueous vehicle is preferred. Published data for terminal sterilization of this specific veterinary grade in multi-dose otic containers is limited; process validation should include assay, related substances, pH, water content and sterility after maximum load.

For premix, granules and powders intended only for non-food-producing companion animals, the API is dry-blended onto a lactose or starch carrier and may be wet-massed or spray-layered depending on the target homogeneity. The low water solubility of the base is less of a problem in solid oral formats, but the bitter taste can reduce palatability; coating or encapsulation may be required in feline or canine oral powders. Blend segregation is a recognised batch-to-batch risk when the API particle size is much finer than the carrier; adhesive mixtures with microfine carriers or granulation can reduce dusting and improve content uniformity under USP <905>. The use of chloramphenicol in any premix, granule or powder destined for food-producing species is not acceptable in the United States under 21 CFR 530.41 and in the European Union under Commission Regulation (EU) No 37/2010. This regulatory boundary is the primary difference from florfenicol-containing premixes, which are approved in several regions for cattle, swine and aquaculture with species-specific MRLs.

When 21 CFR 530.41 Prohibits Food-Animal Application

The regulatory status of chloramphenicol is decisive for product selection. In the United States, extralabel use of chloramphenicol in food-producing animals is prohibited under 21 CFR 530.41. In the European Union, chloramphenicol is included in Table 2 of Commission Regulation (EU) No 37/2010 as a prohibited substance for food-producing species, with no maximum residue limit. This means the veterinary-grade API can be used in tablets, capsules, otic solutions and injectables for companion animals or non-food species where local regulations permit, but it cannot be used in feed premixes or oral powders for livestock, poultry, or aquaculture. The restriction is driven by the potential for dose-independent aplastic anemia in humans and the difficulty in establishing a safe residue concentration. Florfenicol and thiamphenicol have different para-substituent chemistry and toxicological profiles; florfenicol is regulated with MRLs in edible tissues for certain production species. These regulatory and toxicological differences, not merely antimicrobial spectra, determine the choice of API in food-animal markets.

Comparing the Nitro and Methylsulfonyl Derivatives

Chloramphenicol base differs from florfenicol and thiamphenicol primarily in the para substituent of the aromatic ring. Chloramphenicol contains a para-nitro group, whereas florfenicol and thiamphenicol contain a methylsulfonyl substituent. The nitro group is structurally associated with the rare but serious dose-independent aplastic anemia reported in humans; the methylsulfonyl derivatives are not considered free of bone-marrow effects but have a different regulatory and safety position. Florfenicol has an additional fluorine at the C-3 position and is approved for food-animal indications in several regions; thiamphenicol is used in human and veterinary medicine in some jurisdictions but its food-animal status varies. The water solubility of chloramphenicol base is approximately 2.5 mg/mL at 25 °C; solubility data for florfenicol and thiamphenicol vary by polymorph and salt form, so direct numerical comparison must be made against the exact registered source. The base API is not directly interchangeable with chloramphenicol sodium succinate or chloramphenicol palmitate; the ester prodrugs have different molecular weights, solubility, and hydrolysis kinetics. When switching a formula from base to ester, the stoichiometric equivalence factor must be calculated from the molecular weight of the chosen derivative.

Storage of the bulk API is specified as well-closed containers protected from light at controlled room temperature under USP <659>. The material should not be exposed to strong alkali, and prolonged contact with primary amines or high-pH buffer species should be avoided because the amide linkage and nitro group are reactive under reducing or strongly basic conditions. Residual moisture above the compendial limit increases hydrolytic risk; if the API is dried before use, the drying temperature should not exceed 60 °C unless process validation demonstrates no related-substance increase. The micronized form may be more hygroscopic and static-prone; handling in low-humidity environments below 40% RH reduces caking and equipment buildup. Containment measures should follow veterinary API occupational exposure limits and local environmental release limits because the compound’s toxicological profile requires control of dust generation.